ZA200407813B - Medicament for preventing and/or treating chronic rejection. - Google Patents

Medicament for preventing and/or treating chronic rejection.

Info

Publication number
ZA200407813B
ZA200407813B ZA200407813A ZA200407813A ZA200407813B ZA 200407813 B ZA200407813 B ZA 200407813B ZA 200407813 A ZA200407813 A ZA 200407813A ZA 200407813 A ZA200407813 A ZA 200407813A ZA 200407813 B ZA200407813 B ZA 200407813B
Authority
ZA
South Africa
Prior art keywords
medicament
preventing
treating chronic
chronic rejection
rejection
Prior art date
Application number
ZA200407813A
Other languages
English (en)
Inventor
Masakazu Kobayashi
Fan Pan
Aaron Ebbs
Hongsi Jiang
Lurie Erickson
Carmen Wynn
Original Assignee
Merger Into Astellas Pharma In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merger Into Astellas Pharma In filed Critical Merger Into Astellas Pharma In
Publication of ZA200407813B publication Critical patent/ZA200407813B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200407813A 2002-04-16 2004-09-28 Medicament for preventing and/or treating chronic rejection. ZA200407813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37241902P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
ZA200407813B true ZA200407813B (en) 2005-10-18

Family

ID=29250850

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200407813A ZA200407813B (en) 2002-04-16 2004-09-28 Medicament for preventing and/or treating chronic rejection.

Country Status (18)

Country Link
US (2) US20030232867A1 (fr)
EP (1) EP1494669A1 (fr)
JP (1) JP2005526107A (fr)
KR (1) KR20040101381A (fr)
CN (1) CN1646122A (fr)
AR (1) AR039416A1 (fr)
AU (1) AU2003223119A1 (fr)
BR (1) BR0309427A (fr)
CA (1) CA2481184A1 (fr)
IL (1) IL164185A0 (fr)
MX (1) MXPA04010170A (fr)
NO (1) NO20044272L (fr)
NZ (1) NZ535692A (fr)
PL (1) PL372902A1 (fr)
RU (1) RU2004133347A (fr)
TW (1) TW200306825A (fr)
WO (1) WO2003086391A1 (fr)
ZA (1) ZA200407813B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2698508T3 (es) 2009-04-22 2019-02-05 Askat Inc Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2014037832A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques
EP2847158A4 (fr) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions et méthodes pour le traitement des troubles neuromusculaires et des troubles neurodégénératifs
WO2013167991A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles métaboliques
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168012A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles respiratoires
WO2013168004A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur fibromyalgique
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167999A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168005A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome des jambes sans repos et de la fibromyalgie
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168001A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur modérée à sévère
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168000A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur sévère
WO2013168015A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de l'asthme et de l'allergie
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873104A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la mucosite
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (fr) 2012-09-08 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (fr) 2013-06-04 2014-12-11 Mahesh Kandula Compositions et procédés de traitement du diabète et du pré-diabète
WO2016110865A1 (fr) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus

Also Published As

Publication number Publication date
NZ535692A (en) 2006-07-28
BR0309427A (pt) 2005-02-01
AU2003223119A1 (en) 2003-10-27
EP1494669A1 (fr) 2005-01-12
PL372902A1 (en) 2005-08-08
US20030232867A1 (en) 2003-12-18
AR039416A1 (es) 2005-02-16
MXPA04010170A (es) 2005-02-03
IL164185A0 (en) 2005-12-18
RU2004133347A (ru) 2005-05-10
CA2481184A1 (fr) 2003-10-23
WO2003086391A1 (fr) 2003-10-23
CN1646122A (zh) 2005-07-27
JP2005526107A (ja) 2005-09-02
TW200306825A (en) 2003-12-01
US20060211725A1 (en) 2006-09-21
KR20040101381A (ko) 2004-12-02
NO20044272L (no) 2004-12-15

Similar Documents

Publication Publication Date Title
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
EP1487492A4 (fr) Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents
ZA200503967B (en) Agent for preventing or treating neuropathy
AP2005003212A0 (en) Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EP1535971A4 (fr) Pigment traite, son utilisation, et compose destine au traitement de pigments
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
PT1596868E (pt) Método para o tratamento de insuficiência cardíaca grave e medicamento associado
GB2425617B (en) Device for preventing and treating myopia
EP1575582A4 (fr) Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
EP1726313A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose
EP1590271A4 (fr) Systeme de traitement de pieces et ensemble convoyeur
ZA200210316B (en) Composition and its therapeutic use.
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
GB2388557B (en) Treatment system
WO2004080477A8 (fr) Aplidine utilisee dans le traitement du myelome multiple
AU2003302915A1 (en) Waste-water filter, waste-water treatment device and method incorporating the waste-water filter
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes